The official position of the Society for Clinical Trials is to support legislation in the United States and internationally that mandates registration of all controlled clinicals trials at or before enrollment of the first participant. The major trial sponsor would be responsible for ensuring contribution of trial information. The mechanism for registering trials would be through research ethics review boards, and registration would be required for ethics approval and before trial initiation. Standardized data and a unique identification number would be available for each registered trial.
Get full access to this article
View all access options for this article.
References
1.
1. The Society for Clinical Trials Purpose. Available at: http://www.sctweb.org/purpose.cfm. (last accessed 10 August 2004).
2.
2. Dickersin K.Reportfromthe panel onthe casefor registers of clinical trials at the Eighth Annual Meeting of the Society for Clinical Trials. Control Clin Trials1988; 9: 76–81.
3.
3. Dickersin K, Chan S, Chalmers TC, Sacks HS, Smith H Jr.Publication bias and clinical trials. Control Clin Trials1987; 8: 343–353.
4.
4. Chalmers I, Hetherington J, Newdick M et al. The Oxford Database of Perinatal Trials: developing a register of published reports of controlled trials. Control Clin Trials1986; 7: 306–324.
5.
5. Meinert CL. Toward prospective registration of clinical trials. Control Clin Trials1988; 9:1–5.
6.
6. Simes RJ. Publication bias: the case for an international registry of clinical trials. J Clin Oncol1986; 4: 1529–1541.
7.
7. Hetherington J, Dickersin K, Chalmers I, Meinert CL. Retrospective and prospective identification of unpublished controlled trials: lessons from a survey of obstetricians and pediatricians. Pediatrics1989; 84: 374–380.
8.
8. Chalmers TC. Randomize the first patient!N Engl J Med1977; 296: 107-107.
9.
9. Ad Hoc Working Party of the International Collaborative Group on Clinical Trials Registries. Position paper and consensus recommendations on clinical trial registries. Clin Trials Metaanal1993; 28: 199–201.
10.
10. Dickersin K, Manheimer E, Wieland LS, Robinson KA, Lefebure C, McDonald S, and the CENTRAL Development Group. Development of The Cochrane Collaboration's Central Register of controlled clinical trials. Eval Health Prof2002; 25: 38–47.
12. Scherer R, Langenberg P. Full publication of results initially presented in abstracts [Cochrane Methodology Review], Oxford, England: Cochrane Library, Update Software; 2003; issue 1.
13.
13. Dickersin K. How important is publication bias? A synthesis of available data. AIDS Educ Prev1997; 9(suppl.): 15–21.
14.
14. Chalmers I. Underreporting research is scientific misconduct. JAMA1990; 263: 1405–1408.
15.
15. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: Systematic review of published versus unpublished data. Lancet2004; 363: 1341–1345.
16.
16. Moore T. Deadly medicine: why tens of thousands of heart patients died in Azmerica's worst drug disaster. New York, NY: Simon & Schuster, 1995.
17.
17. Furberg CD. Effect of antiarrhythmic drugs on mortality after myocardial infarction. Am J Cardiol1983; 52: 32C–36C.
18.
18. Cowley AJ, Skene A, Stainer K, Hampton JR. The effect of lorcainide on arrhythmias and survival in patients with acute myocardial infarction: an example of publication bias. Int J Cardiol1993; 40: 161–166.
19.
19. Chalmers I. Using systematic reviews and registers of ongoing trials for scientific and ethical trials design, monitoring, and reporting. In: Egger M, Smith GD, Altman DG eds. Systematic reviews in health care: meta-analysis in context. London, UK: BMJ Books, 2001: 429–443.
20.
20. Levine J, Guy W, Cleary P. Therapeutic trials of psychopharmacologic agents: 1968–1972. In McMahon G ed. Psychopharmacological agents. Armonk, NY: Futurea Publishing Co1974.
21.
21. Dickersin K. Why register clinical trials? – revisited. Control Clin Trials1992; 13: 170–177.
22.
22. Dickersin K, Garcia-Lopez F. Regulatory process effects clinical trial registration in Spain. Control Clin Trials1992; 13: 507–512.
23.
23. Anderson D, Costa I, Dickersin K. Building Trials- Central, an online register of clinical trials registers. Control Clin Trials2001; 22: 40S-40S.
24.
24. McCray AT. Better access to information about clinical trials. Ann Intern Med. 2001; 133: 609–614.
25.
25. The UK National Health Service. The UK National Health Service, National Research Register; Available at: http://www.dh.gov.uk/PublicationsAndStatistics/Publications/PublicationsPolicyAndGuidance/PublicationsPolicyAndGuidanceArticle/fs/en?Content_ID=4075210&chk=F4QsHF, accessed 30 May 2004.
26.
26. Manheimer E, Anderson D. Survey of public information about ongoing clinical trials funded by industry: evaluation of completeness and accessibility. Br Med J2002; 325: 528–531.
27.
27. Toigo T. Food and Drug Modernization Act (FDAMA) Section 113: Status Report on Implementation. J Biolaw Business2004; 7: in press.
28.
28. Tonks A. A clinical trials register for Europe. BMJ2002; 325: 1314–1315.
29.
29. Horton R, Smith R. Time to register randomised trials. The case is now unanswerable. Br Med J1999; 319: 865–866.
30.
30. European Science Foundation. European Science Foundation Policy Briefing No. 13, May 2001. Controlled clinical trials. Available at http://www.esf.org/publication/909/ESPB13.pdf. accessed 4 May 2004.
31.
31. Evans T, Gulmezolglu M, Pang T. Registering clinical trials: an essential role for WHO. Lancet2004; 363: 1413–1414.
32.
32. Committee on Assessing the System for Protecting Human Research Participants. Responsible Research. A systems approach to protecting research participants. Washington, DC. National Academy of Sciences Press, 2002.
33.
33. Blunt J. Research ethics committees must ensure registration of research and accessibility of results. Br Med J1998; 316: 312-312.
34.
34. Vale CL, Stewart LA. The International Standard Randomised Controlled Trial Number (ISRCTN): what does it mean for reviewers? In Proceedings of the 9th International Cochrane Colloquium; 2001; Lyon, France.
